Coronavirus Knocks Drug Pricing Down – But Not Off – Political Priority List In US
Executive Summary
When the top US health official testified before Congress on the budget this past week, drug pricing was barely discussed. What a difference two weeks – and global spread of a novel infectious disease – makes.
You may also be interested in...
How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.
Market For COVID-19 Therapeutics Will Exceed Government Demand, US Believes
HHS Secretary Azar says $1bn of the $2.5bn emergency supplemental funding request is for vaccine development.
Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.